TY - JOUR
T1 - Trends in revascularization therapies for patients with acute stroke with large infarcts
T2 - a population-based study
AU - Catalan Stroke Code Registry (CatSCR) Consortium
AU - Doncel-Moriano Cubero, Antonio
AU - Rodríguez-Vázquez, Alejandro
AU - Rosa, Irene
AU - Rudilosso, Salvatore
AU - Serrano, Mònica
AU - Renú, Arturo
AU - Cabero-Arnold, Andrea
AU - Blasco, Jordi
AU - Amaro, Sergi
AU - Llull, Laura
AU - Molina, Carlos A.
AU - Cardona Portela, Pere
AU - Camps-Renom, Pol
AU - Millan, Mónica
AU - Figueras-Aguirre, Georgina
AU - Rodríguez-Campello, Ana
AU - Silva, Yolanda
AU - Purroy, Francisco
AU - Salvat, Mercè
AU - Vargas, Martha
AU - Urra, Xabier
AU - Chamorro, Ángel
AU - Cardona, Pere
AU - Quesada, Helena
AU - Lara, Blanca
AU - Paipa, Andrés
AU - Núñez Guillen, Ana
AU - Aja, Lucia
AU - Mora, Paloma
AU - Chirife, Oscar
AU - Aixut, Sonia
AU - Ángeles de Miquel, María
AU - Molina, Carlos
AU - Rubiera, Marta
AU - Pagola, Jorge
AU - Rodríguez-Luna, David
AU - Muchada, Marian
AU - Tomasello, Alejandro
AU - Ribó, Marc
AU - Requena, Manuel
AU - Garcia-Tornel, Alvaro
AU - Olivé, Marta
AU - Rodriguez, Noelia
AU - Juega, Jesus
AU - Rizzo, Federica
AU - Taborda, Belén
AU - de Dios, Marta
AU - Hernández, David
AU - Chamorro, Ángel
AU - Amaro, Sergio
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
PY - 2025
Y1 - 2025
N2 - Background: Evidence from randomized clinical trials shows that mechanical thrombectomy (MT) enhances functional outcomes in patients with large core ischemic stroke. Objective: To evaluate trends in the use of revascularization therapies, particularly MT, and their impact on functional outcomes in patients with large core ischemic stroke in routine clinical settings. Methods: Observational data from the Stroke Code Registry of Catalonia (CICAT, 2016-2024) were analyzed. Patients with anterior circulation ischemic stroke and Alberta Stroke Program Early CT Score (ASPECTS) <6, whether treated with reperfusion therapies or not, were included. Statistical analyses included trend analysis and multivariable logistic regression to identify predictors of favorable outcomes (modified Rankin Scale score 0-3 at 90 days) and mortality. Results: Among 599 patients, MT use increased significantly from 22% pre-2022 to 36% post-2022. This increase was associated with improved functional outcomes, with favorable outcomes rising from 29% to 43% post-2022. MT was a significant independent predictor of favorable outcomes (OR 3.4, 95% CI 2.1 to 5.5) and reduced mortality (OR 0.46, 95% CI 0.32 to 0.68). Intravenous thrombolysis also improved outcomes (OR 2.1, 95% CI 1.3 to 3.5). The benefit of MT was consistent across ASPECTS subgroups (0-2 and 3-5). Mediation analysis indicated that 88% of improvement could be attributed to increased MT use. Conclusions: Increased MT use significantly improved outcomes for patients with large core ischemic stroke, particularly after 2022. Benefits were observed across subgroups, including those with very low ASPECTS. These findings support broadening MT access and suggest the need to update treatment guidelines to consider patients with large ischemic cores, aiming to optimize outcomes in routine clinical practice.
AB - Background: Evidence from randomized clinical trials shows that mechanical thrombectomy (MT) enhances functional outcomes in patients with large core ischemic stroke. Objective: To evaluate trends in the use of revascularization therapies, particularly MT, and their impact on functional outcomes in patients with large core ischemic stroke in routine clinical settings. Methods: Observational data from the Stroke Code Registry of Catalonia (CICAT, 2016-2024) were analyzed. Patients with anterior circulation ischemic stroke and Alberta Stroke Program Early CT Score (ASPECTS) <6, whether treated with reperfusion therapies or not, were included. Statistical analyses included trend analysis and multivariable logistic regression to identify predictors of favorable outcomes (modified Rankin Scale score 0-3 at 90 days) and mortality. Results: Among 599 patients, MT use increased significantly from 22% pre-2022 to 36% post-2022. This increase was associated with improved functional outcomes, with favorable outcomes rising from 29% to 43% post-2022. MT was a significant independent predictor of favorable outcomes (OR 3.4, 95% CI 2.1 to 5.5) and reduced mortality (OR 0.46, 95% CI 0.32 to 0.68). Intravenous thrombolysis also improved outcomes (OR 2.1, 95% CI 1.3 to 3.5). The benefit of MT was consistent across ASPECTS subgroups (0-2 and 3-5). Mediation analysis indicated that 88% of improvement could be attributed to increased MT use. Conclusions: Increased MT use significantly improved outcomes for patients with large core ischemic stroke, particularly after 2022. Benefits were observed across subgroups, including those with very low ASPECTS. These findings support broadening MT access and suggest the need to update treatment guidelines to consider patients with large ischemic cores, aiming to optimize outcomes in routine clinical practice.
KW - Stroke
KW - Thrombectomy
KW - Thrombolysis
UR - http://www.scopus.com/inward/record.url?scp=105004905462&partnerID=8YFLogxK
U2 - 10.1136/jnis-2025-023252
DO - 10.1136/jnis-2025-023252
M3 - Article
C2 - 40316318
AN - SCOPUS:105004905462
SN - 1759-8478
JO - Journal of NeuroInterventional Surgery
JF - Journal of NeuroInterventional Surgery
M1 - jnis-2025-023252
ER -